“A Comprehensive Review on Selective Dual Inhibitor NSAID - Polmacoxib”

Abstract

The review article provides extensive overview on the promising pharmaceutical compound, polmacoxib also known as CG100649, explaining its pharmacological properties, chemical and physical properties, clinical studies and analytical methods. Polmacoxib is a novel nonsteroidal anti-inflammatory drug (NSAID) that has shown significant interest in recent years for its potential therapeutic benefits in Osteoarthritis treatment and distinct analytical characteristics. The chemical and pharmacological section in this review depicts the choice of solvents to be used through its solubility profile and the mechanism of action which focuses on inhibition of both cyclooxygenase-2 (COX-2) and carbon anhydrase inhibition with subsequent modulation of prostaglandin synthesis. The clinical trial of polmacoxib shows especially the phase 3 trial explains majorly about the safety and efficacy of the drug and explains why it is the chosen one among other NSAIDs. Data from randomized controlled trials and observational studies provides understanding of its use in patient population, expressing its potential as an alternate NSAID. Analytical methods for polmacoxib, such as Reverse Phase High Performance Liquid Chromatography (RP-HPLC), Differential Scanning Calorimetry (DSC), and Powder X-Ray Diffraction (PXRD) are highlighted in this review. The RP-HPLC is developed for quantification of drug, while DSC and PXRD reveals about the solid-state property of CG100649 which will be useful in formulation and stability studies. In conclusion, this review article provides critical information regarding the drug Polmacoxib with its chemical and pharmacological properties, trials conducted as well as analytical procedures performed. It would clearly serve as a valuable resource for analysts, clinicians, researchers and pharmaceutical professionals in understanding its potential and performing further in-process manufacturing and drug product development